The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Dry-Reagent Double-Monoclonal Assay for Cystatin C

På svenska

Author

  • Noora Ristiniemi
  • Qiu-Ping Qin
  • Alexander Postnikov
  • Anders Grubb
  • Kim Pettersson

Summary, in English

BACKGROUND: Cystatin C is a low molecular weight cysteine proteinase inhibitor whose plasma or serum concentrations have been shown to be better correlated with glomerular filtration rate than serum creatinine concentrations. Routine assays for cystatin C are based on use of polyclonal antibodies and immunoturbidimetric and nephelometric designs. This study aimed to develop a double-monoclonal immunoassay for cystatin C. METHODS: We tested functionality of 42 2-site antibody combinations involving 7 monoclonal antibodies with recombinant and plasma cystatin C. We developed a heterogeneous assay using 2 antibodies selected to give the best analytical performance. The assay used a dilution step and was based on a dry-reagent, all-in-one immunoassay concept with time-resolved fluorometry. The assay was performed on an automated immunoanalyzer in single wells that contained all the required assay components. We used heparin-derived plasma samples for methodological evaluation of the assay. RESULTS: From a relative epitope map involving 7 cystatin C-specific antibodies, we selected a pair of antibodies for a 2-site sandwich-type dry-reagent assay. Total assay time was 15 min, and 10 mu L of a 100-fold diluted sample was used. The analytical detection limit (background + 3SD) and functional detection limit (CV 20%) were 0.01 mg/L and 0.02 mg/L, respectively. Within-run and total assay imprecision were < 4.7% and < 5.6% (at 0.84-3.2 mg/L), respectively, and plasma recoveries of added cystatinCwere 94%-110%. Regression analysis with the Roche particle-enhanced immunoturbidimetric method yielded the following (SD): slope, 1.391 (0.029); y-intercept, - 0.152 (0.045) mg/L; S-y vertical bar x = 0.294 mg/L (n = 31). CONCLUSIONS: The developed assay enables rapid and reliable measurement of cystatin C. (C) 2010 American Association for Clinical Chemistry

Publishing year

2010

Language

English

Pages

1424-1431

Publication/Series

Clinical Chemistry

Volume

56

Issue

9

Document type

Journal article

Publisher

American Association for Clinical Chemistry

Topic

  • Biochemistry and Molecular Biology

Status

Published

ISBN/ISSN/Other

  • ISSN: 0009-9147